The Centers for Medicare & Medicaid Services (CMS ) just announced the first set of drugs and biologics for price negotiations to be effective 2026. Many manufacturers have been anxiously awaiting the initial list since the passing of the Inflation Reduction Act (IRA) last year. As...
What Pharma Manufacturers Need to Know about the Inflation Reduction Act On August 16, 2022, President Biden signed the Inflation Reduction Act (IRA) into law (P.L. 117-169). The IRA is a comprehensive law that includes multiple provisions to provide financial relief for Medicare beneficiaries, improve access...
Do you know your asset's rare disease launch archetype? A rare disease is designated by having less than 200,000 patients in the US. However, when we consider rare diseases as a category, we start to form a different understanding of the scale; they affect 30 million...
Overcoming Launch Challenges and Maximizing Success in a Complex Landscape In the pharmaceutical industry, appropriately allocating resources and planning for a drug launch has never been more crucial. There are new obstacles and challenges with supply chain management and the application of multi-tier pricing. Moreover, as...
Executive Order 14091: Pivotal Opportunity for Healthcare Manufacturers  Understanding the Impact and Strategies for Manufacturers to Address SDoH On February 16, 2023, President Biden signed Executive Order 14091, titled 'Advancing Health Equity and Racial Justice by Addressing the Social Determinants of Health.' This Order has immediate and significant...
Interview with Pharmaceutical Executive Our Partner, Brian Torres, sat down with Pharmaceutical Executive to discuss trends in patient support services, how those trends affect a broader commercialization strategy, and how digital health fits into a product launch. To learn more about our Patient Services Strategy and Design...
